Ocular Therapeutix has successfully completed enrollment in the phase 3 SOL-R clinical trial for wet age-related macular degeneration (AMD), marking a significant milestone in retinal TKI research. This achievement, achieved within a year of conceptualization, highlights the company’s dedication to advancing innovative treatments for patients with wet AMD. The SOL-R trial, the largest of its […]